The Competition and Markets Authority has issued an invitation to comment on the anticipated acquisition by Intersurgical of the acute care and interventional urology businesses of Teleflex Incorporated, the first step in its information gathering on the transaction. Comments on any competition issues are due by November 3, 2026. The authority said it has received the information needed to begin pre-notification but has not yet launched a formal phase 1 investigation.
The case page records a second transaction layered on the first: following the acquisition, control over Intersurgical will be acquired by Armira Capital and TA Associates. The CMA’s assessment therefore covers both the combination of the Teleflex product lines with Intersurgical’s respiratory and acute care range in the UK, and the change of control of the combined buyer to two private equity owners.
Intersurgical is a medical device maker focused on respiratory care, and the Teleflex businesses add acute care and interventional urology products sold into hospitals. Where the two ranges overlap in UK supply, or where the combined group would hold strong positions in adjacent hospital product categories bought by the same NHS and private purchasers, is the question the comment period is designed to surface before the CMA decides whether to open a formal investigation.
No value for either transaction appears in the CMA material, and neither the product revenues at issue nor the sponsors’ price for control of Intersurgical is stated there. The timetable is the hard fact for now: representations close on November 3, after which the case page will record whether a phase 1 investigation commences.